Gene therapy for cardiovascular disease: perspectives and potential

Bradshaw, A. C. and Baker, A. H. (2013) Gene therapy for cardiovascular disease: perspectives and potential. Vascular Pharmacology, 58(3), pp. 174-181. (doi: 10.1016/j.vph.2012.10.008)

Full text not currently available from Enlighten.

Publisher's URL: http://dx.doi.org/10.1016/j.vph.2012.10.008

Abstract

Cardiovascular disease is the most frequent cause of mortality in the western world, accounting for over 800,000 premature deaths per year in the EU alone. Cardiovascular disease is the second most common application for gene therapy clinical trials, which most frequently employ adenovirus serotype 5 (Ad5)-based vectors as delivery vehicles. Although interactions of Ad5 vectors with circulating proteins and cells can limit their efficacy after systemic administration, local gene delivery strategies show great potential in the cardiovascular setting, notably in the context of vascular delivery. Here we review the pathogenesis of bypass graft failure and in-stent restenosis, identifying potential therapeutic targets and discussing recent advances in the field of adenovirus biology and retargeting that, in concert, will potentially translate in coming years to more effective gene therapies for cardiovascular applications.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Baker, Professor Andrew and Bradshaw, Dr Angela
Authors: Bradshaw, A. C., and Baker, A. H.
College/School:College of Medical Veterinary and Life Sciences > Institute of Cardiovascular and Medical Sciences
Journal Name:Vascular Pharmacology
Publisher:Elsevier
ISSN:1537-1891
ISSN (Online):1879-3649
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
519431Interrogation and manipulation of miRNA in acute vascular injuryAndrew BakerBritish Heart Foundation (BHF)RG/09/005/27915RI CARDIOVASCULAR & MEDICAL SCIENCES